1. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)‏
by Stefan Knop, Christian Gerecke, Peter Liebisch, Max S. Topp, Uwe Platzbecker, Orhan Sezer, Christina Vollmuth, Karina Falk, Axel Glasmacher, Uwe Maeder, Hermann Einsele, and Ralf C. Bargou
Blood
Volume 113(18):
April 30, 2009
©2009 by American Society of Hematology

2. Time to progression and overall survival.
Time to progression and overall survival. (A) Kaplan-Meier plot for time to progression (TTP). The vertical axis represents the proportion of patients who are alive and progression-free from first dose of study drug. The horizontal axis represents time in weeks. (B) Kaplan-Meier plot for overall survival (OS). The vertical axis represents the proportion of patients who are alive. The horizontal axis represents the time in weeks from first dose of study drug.
Stefan Knop et al. Blood 2009;113:
©2009 by American Society of Hematology

3. Time to progression in relation to prognostic factors.
Time to progression in relation to prognostic factors. (A) Median TTP depending on normal or elevated (≥ nM [3.5 mg/L]) levels of β2-microglobulin. The vertical axis represents the proportion of patients who are alive and progression-free. The horizontal axis represents time in weeks from first dose of study drug. The solid line represents patients with normal (less than nM) β2-microglobulin (n = 42) and the dotted line represents patients with elevated (≥ nM) β2-microglobulin (n = 17). (B) Median TTP in weeks depending on cytogenetic aberration 17p−. The vertical axis represents the proportion of patients who are alive and progression-free. The horizontal axis represents time in weeks from first dose of study drug. The solid line represents patients without 17p− (n = 32), and the dotted line represents patients with 17p− (n = 5).
Stefan Knop et al. Blood 2009;113:
©2009 by American Society of Hematology